Importantly, it has been previously shown that the genomic landscape of SBA is significantly different in IBD-associated SBA, compared to non-IBD associated, with mutations within the p53 pathway being affected in nearly 70% of all IBD-associated SBA [13]. This evidence concerns the gene TP53 and inflammatory bowel disease.